Testosterone Use Not Tied to Gynecological Cancers in Transmasculine Individuals
By Lori Solomon HealthDay Reporter
FRIDAY, May 16, 2025 -- Short-term testosterone use among transmasculine and gender diverse (TMGD) individuals is not associated with an increased risk for gynecological cancers, according to a study published online May 12 in eClinicalMedicine.
Asra Vestering, M.D., from the Amsterdam University Medical Center, and colleagues evaluated the incidence of gynecological (pre-)malignancies among 1,955 TMGD individuals using testosterone treatment between Feb. 17, 1972, and Dec. 3, 2018.
The researchers found a median duration of testosterone usage of 1.7 years before hysterectomy and oophorectomy (median age, 24 years) and 3.1 years before vaginal and/or vulvar surgery or biopsy (median age, 29 years). No gynecological malignancies were seen, while expected incidence was ≤0.26 for all cancer types. Across samples, one ovarian borderline tumor, one case of simple endometrial hyperplasia, and one case of vulvar intraepithelial neoplasia (VIN) III were detected. The age-adjusted standardized incidence ratio for >VIN2 was 0.23.
"We found no increased risk of these cancers compared to women from the general population. None of these cancers were diagnosed in the entire participant group," Vestering said in a press release. "This is valuable information for both health care providers and transmasculine and gender-diverse people who are considering starting hormone therapy."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
FRIDAY, June 27, 2025 -- For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the addition of neoadjuvant and adjuvant pembrolizumab to standard care...
Telehealth Intervention Beneficial for Seniors With Metastatic Cancer
WEDNESDAY, June 25, 2025 -- The telehealth-administered Geriatric Assessment–Guided Intervention (GAIN-S) improves physical function, mood, quality of life, and prognostic...
Incidence Rates of Appendiceal Adenocarcinoma Increasing
MONDAY, June 16, 2025 -- The incidence rates of appendiceal adenocarcinoma (AA) increased after 1945, according to a study published online June 10 in the Annals of Internal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.